We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Magnesium Pro (Amazing Oils Pty Ltd)
Product Name
Magnesium Pro
Sponsor
ARTG details
- 299947
Date of review outcome
Date of publication
Dec-2025
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
Seek advice from a doctor if you have been taking this medicine to treat anxiety or migraine.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to muscle spasms, sleep quality, restless sleep, inflammation in the body or healthy emotional balance.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to muscle spasms, sleep quality, restless sleep, inflammation in the body or healthy emotional balance.
Review scope
Targeted
Information reviewed
ARTG Record, Labels, Website
Issues related to safety
The website for this medicine contained claims about treating anxiety and migraine. These are serious conditions that require diagnosis, treatment or supervision by a suitably qualified health professional.
Reference to anxiety or migraine without specifying mild forms of these conditions are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitability qualified health professional, which may result in adverse outcomes.
However, the label advised consumers to see a healthcare practitioner if symptoms persist. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
Reference to anxiety or migraine without specifying mild forms of these conditions are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitability qualified health professional, which may result in adverse outcomes.
However, the label advised consumers to see a healthcare practitioner if symptoms persist. As such, this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The label and website for this medicine contained claims specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsors certification that they held evidence to substantiate them.
Actions taken during the review
The sponsor cancelled this medicine and withdrew it from further supply. Nevertheless, the TGA issued an educational letter to the sponsor outlining the issues with this medicine.